The plant investigation is in process.A supplemental mdr will be submitted upon completion of this activity.Clinical review: there was no indication of a serious injury, patient death, or other adverse event related to a fresenius or xenios product, and there was no other issue warranting further investigation.Additionally, there was no allegation of an ultraflux av 600 s malfunction or deficiency related to the event.
|
Plant investigation: the reported complaint could not be confirmed.The complaint sample was not available for evaluation.The described situation is adequately addressed in the instructions for use (ifu) and/or on the label.Due to 100% testing, it is highly unlikely to detect a failure in a retention sample.Furthermore, only a small number of reserve samples are available.Therefore, the retention sample analysis was not done.In the past, extraction of retention samples showed no unusual residuals which could lead to the reported failure.Therefore, it is assumed that the patient allergy/reaction may have been caused by other factors besides the dialyzer, for example, the specific physical/medical status of the patient.A batch record investigation was conducted, and all released products were found to be conforming to specifications.No indication for any relationship with the reported failure mode was found during the review.Based on the information available, the cause for the reported failure could not be traced to the device.
|